ArticleInternational journal of molecular sciences2023
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Austrian treatment algorithms 2025: CDK 4/6 inhibitors in the adjuvant therapy of HR+/HER2- early breast cancer.Wiener klinische Wochenschrift · 2026Review
- Real-World Clinical, Enviro-Logistical and Economic Implications of Sentinel Lymph Node Biopsy Omission in Early Breast Cancer.Annals of surgical oncology · 2026Article
- Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer: insights from a large cohort in central south China.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.Geburtshilfe und Frauenheilkunde · 2026Article
- High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany.Geburtshilfe und Frauenheilkunde · 2026Article
- Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.The Lancet regional health. Europe · 2025Article
- Balancing evidence and individualization in adjuvant CDK4/6 therapy.Translational cancer research · 2025Article
- Therapy of early breast cancer: current status and perspectives.Archives of gynecology and obstetrics · 2025Review
- How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?Acta oncologica (Stockholm, Sweden) · 2025Review
- Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?Geburtshilfe und Frauenheilkunde · 2025Article
- Prognostic implications of risk definitions from the monarchE and NATALEE trials.Journal of the National Cancer Institute · 2025Article
- Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2025Article
- Review
- Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.NPJ breast cancer · 2025Article
- Oral Maintenance Therapy in Early Breast Cancer-How Many Patients Are Potential Candidates?Cancers · 2025Article
- Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).South Asian journal of cancer · 2025Article
- Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.Geburtshilfe und Frauenheilkunde · 2024Article
- Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.Scientific reports · 2024Article
- Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for patients with HR+/HER2- early breast cancer (eBC) at intermediate and high risk of recurrence who were treated with the CDK4/6 inhibitor Ribociclib in combination with endocrine therapy (ET). This retrospective study aims to apply the NATALEE inclusion criteria to a representative real-world cohort to estimate the proportion of HR+/HER2- breast cancer patients eligible for adjuvant Ribociclib therapy. Patients who underwent full surgical treatment for eBC between January 2018 and December 2020 at two large German university breast cancer centers (University of Ulm, University of Tuebingen) were included. Descriptive statistics were used to characterize the patient population eligible for Ribociclib treatment based on the NATALEE study's inclusion criteria. Out of 2384 enrolled patients, 1738 had HR+/HER2- eBC, of whom 43% (747/1738) met the NATALEE inclusion criteria. Of note, these patients were older, received less chemotherapy and presented with less advanced tumor stages compared to the NATALEE study cohort. Additionally, compared to the NATALEE study cohort, fewer patients had lymph node involvement (72.4% vs. 88.7%). Our analysis suggests that approximately 43% of all HR+/HER2- breast cancer patients will qualify for Ribociclib treatment. Given the numerous treatment options for patients with HR+/HER2- eBC, as well as the differences between the NATALEE cohort and patients in the real-world clinical setting, future analyses will be needed to determine which patients would benefit most from adjuvant CDK4/6 inhibitor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.